GSWM
IHE icon

Golden State Wealth Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Golden State Wealth Management’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.64K Buy
+57
New +$5.14K ﹤0.01% 1233

Other funds holding IHE

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return
MCM
Monument Capital Management Alexandria, Virginia $497M AUM 52.58% 1-Year Est. Return
AWM
Accurate Wealth Management Wesley Chapel, Florida $1.05B AUM 30.92% 1-Year Est. Return
FP
FFG Partners Fort Lauderdale, Florida $352M AUM 70.53% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
AFG
Arkansas Financial Group Little Rock, Arkansas $768M AUM 16.55% 1-Year Est. Return
HCMT
Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return
SIA
SeaBridge Investment Advisors Summit, New Jersey $692M AUM 52.26% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Golden State Wealth Management's IHE Position: Q2 2026 in Review

Golden State Wealth Management opened a new position in iShares US Pharmaceuticals ETF (IHE) in Q2 2026: 57 shares worth $5.64K. The stake represents ﹤0.01% of the portfolio and ranks #1233 among its holdings.

45 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

  • Golden State Wealth Management held 57 shares of iShares US Pharmaceuticals ETF worth $5.64K as of Q2 2026.
  • iShares US Pharmaceuticals ETF was a new Golden State Wealth Management position in Q2 2026.
  • iShares US Pharmaceuticals ETF made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1233 holding.
  • 45 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.